This study is for adults with a type of lung cancer called Non-Squamous Non-Small Cell Lung Cancer (NSCLC). Researchers want to find out how well a new drug, livmoniplimab, works when combined with another drug, budigalimab, plus chemotherapy, compared to another drug called pembrolizumab plus chemotherapy. The study will have two stages and last about 55 months. Participants will be given different doses of these drugs to find the best one. Chemotherapy involves medicine given through a needle into a vein (IV).

To join, you need to have a confirmed diagnosis of this type of lung cancer and not have certain mutations. You should also have at least one tumor that can be measured and a life expectancy of at least three months. You cannot have had prior treatment for this cancer.

• Participation may involve more visits and tests than usual care.
• The study will include up to 840 participants and be conducted at 200 sites worldwide.
• Regular visits to a hospital or clinic for medical assessments, blood tests, and scans will be required.